First quarter sell-off signals minor Q2 market adjustment, reveals BioCentury 2Q15 Financial Markets Preview.
The first quarter closed down 6% in BioCentury 100 Index and 5% in NYSE Biotechnolo Index, but analysts anticipate the correction to be temporary in Q2, according to BioCentury 2Q15 Financial Markets Preview, produced with Merrill DataSite. Since the last major market shift in 2008, biotech has been boosted by an extended run of clinical and regulatory success. Analysts say Q1 2015 softening ending this bull run may make raising capital easy while share prices continue to rise and IPOs gather pace. Find out which recent acquisitions are contributing to attractive valuations in small and mid-caps—and which company scored the top deal. Track sector IPO trends, and discover which public biotech companies made the strongest showings in 2015 to date.
- IPO queue identifying 18 companies announcing IPOs in 2015 to date, including fundraising ranks
- Quarterly rankings of biotech companies by funds raised and IPO performance